Proactive Investors - Run By Investors For Investors

US$1mln grant testament to Redx Pharma’s ‘innovation and research prowess’

“That [Redx] has attracted such an award is testament to its innovation and research prowess in the development of novel antibiotics”
medical research lab
Shares in the drug developer gained almost 20% this week

Shares in Redx Pharma Plc (LON:REDX) boomed this week after the drug developer was awarded a US$1mln grant from a US-UK partnership set up to accelerate the development of new antibiotics.

The money from CARB-X will allow Redx to move its Gram-negative antibacterial programme into the next stage of development with a prospective partner.

City broker Cantor Fitzgerald said the grant reflects the importance of the antibiotic research being carried out by Redx.

“That this programme has attracted such an award is testament to its innovation and research prowess in the development of novel antibiotics to treat the threat from emerging resistance to Gram-negative bacteria,” wrote analyst Brian White in a note to clients on Friday.

Drug resistant Gram-negative are becoming an increasingly problematic in healthcare settings, White added.

The analyst also points out that to win the award, Redx had to go through a “highly competitive process”. Of the 168 initial applicants, only eleven firms, including Redx, received any form of funding.

“This award is important and timely given that Redx has refocused its business in order to capitalise on its close to clinic candidates in its focus areas of cancer and immunology,” said White.

“Consequently, this external funding allows this important area of research and development to continue.”

The oncology pipeline is still king though, and Redx’s RXC004 first-in-class Porcupine inhibitor programme which targets hard-to-treat cancers is scheduled to enter the clinic later this year.

RXC005 – the best-in-class BTK inhibitor – is set to start clinical trials next year.

White reckons the stock is worth 105p, almost triple its current value.

Shares closed 5% higher at 37.1p on Friday.

View full REDX profile View Profile

Redx Pharma Plc Timeline

CN Research
April 06 2017

Related Articles

The Hydroponics Company: Access latest PPT from Proactive's CEO Sessions
May 19 2017
Dr Andrew Beehag talked medical cannabis products and pathways with investors.
Knee surgery
February 02 2017
The treatment involves removing cellular material from animal and human tissue to leave a matrix which gives a framework for population by the patient’s own cells.
Proteomics International Laboratories: Access latest PPT from Proactive's CEO Sessions
April 13 2017
Richard Lipscombe talked revenue generation and growth path with investors.

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use